- A randomised controlled pilot trial of oral 11β-HSD1 inhibitor
- 2 AZD4017 for wound healing in adults with type 2 diabetes mellitus
- 3 Single Sentence Summary
- 4 AZD4017 was safe; data suggested improved skin healing / integrity, and modestly reduced
- 5 epidermal barrier function in patients with type 2 diabetes.
- 6 Authors
- 7 Ramzi Ajjan<sup>1</sup>, Elizabeth MA Hensor <sup>2,3</sup>, Kave Shams<sup>2,4</sup>, Francesco Del Galdo<sup>2,3</sup>, Afroze Abbas<sup>1</sup>, Janet
- 8 Woods<sup>5</sup>, Rebecca J Fairclough<sup>6</sup>, Lorraine Webber<sup>7</sup>, Lindsay Pegg<sup>7</sup>, Adrian Freeman<sup>6</sup>, Ann Morgan<sup>1,3</sup>,
- 9 Paul M Stewart<sup>3,8</sup>, Angela E Taylor<sup>9</sup>, Wiebke Arlt<sup>9</sup>, Abd Tahrani<sup>9</sup>, David Russell<sup>1,5</sup> and Ana Tiganescu<sup>1,3</sup>
- 10 Affiliations
- 11 Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK
- 12 Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
- 13 <sup>3</sup>NIHR Biomedical Research Center, Leeds Teaching Hospitals, NHS Trust, Leeds, UK
- 14 <sup>4</sup>Leeds Centre for Dermatology, Chapel Allerton Hospital, Leeds, UK
- 15 Leeds Vascular Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK
- 16 <sup>6</sup>Emerging Innovations Unit, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge,
- 17 UK
- <sup>7</sup>Emerging portfolio development, Late Oncology, Oncology R&D, AstraZeneca, Cambridge, UK
- 19 \*Faculty of Medicine and Health, University of Leeds, Leeds, UK
- <sup>9</sup>Institute of Metabolism and Systems Research (IMSR), University of Birmingham, Birmingham, UK;
- 21 Centre of Endocrinology Diabetes and Metabolism (CEDAM), Birmingham Health partners,
- 22 Birmingham, UK; Department of Diabetes and Endocrinology, University Hospitals Birmingham NIHS
- 23 Foundation Trust, Birmingham, UK

24 25 Acronym: Glucocorticoids and Skin Healing in Diabetes (GC-SHEALD) 26 Glucocorticoid Keywords: 27 Skin 28 Wound healing 29 11 beta hydroxysteroid dehydrogenase type 1 30 Type 2 diabetes mellitus 31 Randomised controlled trial 32 Corresponding author: Ana Tiganescu 33 Leeds Institute of Cardiovascular and Metabolic Medicine 34 School of Medicine, LIGHT Building, Clarendon Way 35 University of Leeds, LS2 9JT, UK 36 0113 34 38336 37 a.tiganescu@leeds.ac.uk 38 Disclosure Summary: I certify that neither I nor my co-authors have a conflict of interest as described 39 above that is relevant to the subject matter or materials included in this Work.

## **Abstract**

40

41 Chronic wounds (e.g. diabetic foot ulcers) have a major impact on quality of life, yet treatments remain limited. Glucocorticoids impair wound healing; preclinical research suggests that blocking 42 43 glucocorticoid activation by the enzyme  $11\beta$ -hydroxysteroid dehydrogenase type 1 ( $11\beta$ -HSD1) improves wound repair. This investigator-initiated double-blind, randomised, placebo-controlled 44 parallel-group phase 2b pilot trial investigated efficacy, safety and feasibility of 11β-HSD1 inhibition 45 for 35 days by oral AZD4017 (AZD) treatment in adults with type 2 diabetes (n=14) compared to 46 47 placebo (PCB, n=14) in a single-centre secondary care setting. Computer-generated 1:1 48 randomisation was pharmacy-administered. From 300 screening invitations, 36 attended, 28 were 49 randomised. There was no proof-of-concept that AZD inhibited 24 hour skin 11β-HSD1 activity at day 50 28 (primary outcome: adjusted difference AZD-PCB 90% CI (diffCI)=-3.4,5.5) but systemic 11β-HSD1 51 activity (median urinary [THF+alloTHF]/THE ratio) was 87% lower with AZD at day 35 (PCB 1.00, AZD 0.13. diffCl=-1.04,-0.69). Mean wound gap diameter (mm) following baseline 2mm punch biopsy was 52 53 34% smaller at day 2 (PCB 1.51, AZD 0.98, diffCI=-0.95,-0.10) and 48% smaller after repeat wounding 54 at day 30 (PCB 1.35, AZD 0.70, diffCl=-1.15,-0.16); results also suggested greater epidermal integrity 55 but modestly impaired barrier function with AZD. AZD was well-tolerated with minimal side effects 56 and comparable adverse events between treatments. Staff availability restricted recruitment 57 (2.9/month); retention (27/28) and data completeness (95.3%) were excellent. These preliminary 58 findings suggest that AZD may improve wound healing in patients with type 2 diabetes and warrant 59 a fully-powered trial in patients with active ulcers. [Trial Registry: www.isrctn.com/ISRCTN74621291. 60 Funding: MRC Confidence in Concept and NIHR Senior Investigator Award.]

3

## Introduction

61

62 Chronic, non-healing wounds e.g. diabetic foot ulcers are a common worldwide health problem that 63 have substantial medical and socioeconomic importance and represent a major unmet clinical need 64 (1). In Europe, 1-1.5% of the population has a problem wound at any one moment in time. The 65 average cost per episode is 6,650€ for leg ulcers and 10,000€ for foot ulcers, accounting for 2-4% of the healthcare budget and likely to escalate with an increasingly elderly and diabetic population (2). 66 67 In the West Yorkshire UK region the overall prevalence of wounds is 2.8-3.6 people per 1000 68 population (3), up to 50% of which are chronically inflamed, non-healing wounds. Costs for wound 69 care in the UK are estimated at £2.03-3.8 million per 100,000 population (4) and diabetes currently 70 accounts for approximately 10% of the total health resource expenditure and is projected to 71 increase to 17% by 2035 (5). 72 The profound atrophic effects of glucocorticoids (GC) on human skin structure and function are well 73 documented, causing decreased collagen content, increased transepidermal water loss (TEWL), 74 dermal and epidermal thinning, telangiectasia, impaired wound healing (WH) and increased 75 infection risk (6-13). Keratinocytes, melanocytes, fibroblasts and sebocytes play significant roles as 76 GC targets in these processes (11, 14). These effects arise from GC excess including systemic (7, 8) and topical (10) GC therapy, Cushing's disease (6) and psychological stress (13, 15-17). 77 78 The expertise of our group has focused on 11β-hydroxysteroid dehydrogenase (11β-HSD) isozymes 79 which regulate local GC availability in many tissues largely independently of circulating levels (18). In 80 skin, 11β-HSD1 generates cortisol from cortisone, is expressed in epidermal keratinocytes, hair 81 follicles, sebaceous glands and dermal fibroblasts and is upregulated by GC in a forward-feedback 82 manner (19, 20). Conversely, 11β-HSD2 converts cortisol to cortisone and, in skin, is predominantly 83 expressed in eccrine (sweat) glands where it functions to protect the mineralocorticoid receptor 84 from inappropriate activation by GC (as with other mineralocorticoid-responsive tissues e.g. kidney) 85 (21). We recently demonstrated increased  $11\beta$ -HSD1 activity during the inflammatory phase of wound healing in a mouse model (22) and faster healing in 11β-HSD1-null mice treated with oral 86 87 corticosterone (active GC in mouse) and topical application of carbenoxolone (CBX), an 11β-HSD 88 non-selective inhibitor (23). Strikingly, mice with global deletion of 11β-HSD1 were also protected 89 from age-induced dermal atrophy, with improved collagen processing and accelerated wound 90 healing (19). Others have also reported accelerated wound healing by 11β-HSD1 blockade in animal 91 models of diabetes and GC excess (24, 25). 92 These findings suggest that  $11\beta$ -HSD1 mediates the effects of circulating GC in skin and drives the 93 cutaneous consequences of GC excess. However, the role of 11\( \textit{B-HSD1} \) in regulating skin function in 94 man remains unexplored, despite evidence that 11β-HSD1 is upregulated by pro-inflammatory 95 cytokines e.g. IL-1 $\beta$  and TNF (26-28) abundant in chronic wounds, and reports of increased systemic 96 GC levels in patients with type 2 diabetes mellitus (T2DM) (29, 30). Moreover, pro-inflammatory 97 cytokines and GC synergistically increase  $11\beta$ -HSD1 expression (31) which may exacerbate GC 98 availability and further impede wound healing. 99 Targeting 11β-HSD1 through selective inhibitors has been a focus of major pharma for the last 10 100 years, the main target indication being metabolic syndrome to improve glucose tolerance, reduce 101 hepatic gluconeogenesis, steatosis and visceral adipogenesis. Proof of concept was established in a

hepatic gluconeogenesis, steatosis and visceral adipogenesis. Proof of concept was established in a

102 number of phase 2 studies but effect size prevented progression to phase 3 studies (32-35). 103 However, the ability of systemic  $11\beta$ -HSD1 inhibitors to target enzyme activity in skin and regulate 104 skin function in humans is unknown. 105 Our trial objectives were to generate efficacy, safety and study feasibility data to inform a future 106 confirmatory phase 2b trial in patients with diabetic foot ulcers. Our study variables were a 107 combination of validated disease-related outcomes and skin-specific measures previously 108 unexplored in T2DM that greatly improve our knowledge GC metabolism as a regulator of skin 109 function. Results 110 111 A Consolidated Standards of Reporting Trials (CONSORT) flow diagram is presented in Figure 1. 112 **Feasibility** 113 Assessment of recruitment, eligibility, consent and data completeness found conduct of a future confirmatory trial to be feasible. Further details are provided in Appendix 1. 114 115 Participant demographics and baseline variables 116 Participant demographics, baseline efficacy and laboratory safety variables are presented in Table 1. 117 Full descriptive summaries of efficacy and laboratory safety variables are presented in Tables S1 and 118 S2, respectively. The two randomised arms were well balanced for efficacy and safety variables with 119 the possible exception of sudomotor function in the feet and platelets, which were higher and 120 diastolic BP which was lower in the AZD4017 arm. 121 Compliance 122 Mean diary card compliance was >97.9% across both arms at all visits and >99.6% at day 35. Mean 123 IMP compliance at each visit was >95.2% across both arms and reached >97.9% at day 35; overall 124 IMP compliance was 84-101% (PCB) and 93-101% (AZD4017) (Table S3). Drug exposure data in 125 plasma and skin did not indicate any discrepancies between reported compliance and actual 126 exposure, suggesting participants had correctly adhered to the treatment regimen. Further, in the 127 group receiving AZD4017 (n=12 with data available), there was a moderate correlation of 128 Spearman's rho=0.54 between levels in the skin, taken from the biopsy at day 28, and in plasma 129 samples taken at day 35 (Figure S1). 130 **Efficacy** 131 11β-HSD1 activity in skin 132 Our primary outcome evaluated the ability of AZD4017 to inhibit 11β-HSD1 activity in skin. Median 133 11β-HSD1 activity (% conversion per 24hr) by radioassay at day 28 was similar across treatment 134 groups [adjusted for baseline activity, baseline glycated haemoglobin (HbA1c), age and sex: median PCB=11.8, AZD4017=12.8; difference AZD-PCB (90% CI) 1.1 (-3.4, 5.5)] (Figure 2a, Table 2), similar to 135 136 unadjusted estimates (Table S4) and comparable to baseline (Table 1). Proof-of-concept was not met 137 because median activity was higher in the AZD4017 group than placebo at day 28; all CIs included 0. 138 This conclusion was unaffected after removal of 2 baseline samples which failed QC prior to re-139 imputation (Table S5). Changes from baseline (Tables S6-S7) indicated that activity went down in 140 both PCB and AZD4017 groups, but to a greater extent in PCB.

2 and 122 (22 greate) and to a greater entertain 22.

141 A sensitivity analysis was conducted using an alternative ELISA method, which demonstrated an 142 acceptable correlation with the radioassay method at baseline (rho=0.70) but not day 28 (rho=0.19) 143 (Figure S2, Table 3). In the primary analysis, median activity measured via ELISA was lower in the 144 AZD4017 group, but all CIs included 0. In a sensitivity analysis which excluded an extremely high 145 outlier in the placebo group (Table S5), the median was higher in the AZD4017 group, consistent 146 with the radioassay method finding. Therefore, and mindful of the relatively low levels of exvivo 147 11β-HSD1 activity over 24 hours, there was no proof-of-concept that AZD4017 was able to inhibit 148 11β-HSD1 activity in skin. 149 Systemic 11B-HSD1 activity 150 In contrast to the findings in the skin, systemic 11β-HSD1 activity, measured by urinary 151 [THF+alloTHF]/THE ratio, differed to a substantive degree between groups at day 35. Values were 152 lower in the AZD4017 group; adjusted median PCB=1.00, AZD4017=0.13; difference (90% CI) -0.87 153 (1.04, -0.69) (Figure 2b, Table 2). All supplementary CI up to 95% excluded 0. This suggests median 154 systemic 11β-HSD1 activity may be ≥69% (median 87%) lower in subjects taking AZD4017. As 155 anticipated, there was no evidence that urinary F/E ratio (a measure of systemic 11β-HSD2 which 156 deactivates cortisol to cortisone; unplanned analysis) was affected by AZD4017 (Figure 2c, Table 2). 157 Wound healing 158 Separate biopsies were taken at baseline and day 28 from the outer forearm. In each case, based on 159 maximal granulation tissue width (a marker of early wound healing), there was preliminary evidence 160 that the mean wound gap 2 days following the biopsy differed between groups, at all levels of 161 confidence. The 90% CI suggested that the mean gap was potentially 7% to 63% (mean 34%) 162 narrower at day 2 and 12% to 85% (mean 48%) narrower at day 30 in the AZD4017 group, relative to 163 placebo (Figure 3a-b, Table 2). Representative wound healing images for participants treated with placebo and ADZ4017 (Figure 3c) are presented. 164 165 Based on maximal clot depth (a marker of late wound healing), when re-measured 7 days post 166 biopsy, there was no preliminary evidence of a difference between groups at either time-point (on 167 days 7 and 35, Table 2). 168 Epidermal barrier function 169 Resting transepidermal water loss (TEWL), the gold-standard measure of epidermal barrier function, 170 was on average 33% higher in the AZD4017 group on day 35 (Figure 3d, Table 2), suggesting a 171 potentially deleterious effect on epidermal barrier function. Although CIs were wide, some excluded 172 0; at 85% confidence the results suggested between +1% and +75% higher TEWL in the AZD4017 173 group, but the 90% CI was -3% to +82%. 174 Sensitivity analysis re-estimated the 90% CI to be +3% to +88% (Table S5). 175 Epidermal integrity 176 The number of tapes required to achieve a barrier disruption TEWL of  $40-50 \text{ g/h/m}^2$  on day 28 was observed to be higher in the AZD4017 group (at all levels of confidence). The 90% CI indicated 177 178 preliminary evidence of a difference of between +7% and +91% (mean +43%) relative to placebo (Figure 3e, Table 2). This was equivalent to an additional 16.8 tapes required to induce a comparable 179 180 degree of barrier disruption in the AZD4017 group.

181 Epidermal barrier recovery 182 In the first set of post-disruption recovery measurements, collected between baseline and day 7, there was no proof-of-concept for a difference in TEWL; all CIs straddled 1 (Table 2). 183 184 In the second set, collected between day 28 and day 35, there was some preliminary evidence of 185 potential differences in 3hr and 48hr recovery, although Cls were wide. For 3hr post-disruption, the 186 90% CI included 0 (-1% to +79%) but with 85% confidence, this may be between 3% and 72% higher 187 (mean +33%) in the AZD4017 group following 28 days of treatment (Figure 3f, Table 2). Similarly, the 188 primary 90% CI included 0 for 48hr post-disruption TEWL (-6% to 67%), but at 80% confidence there 189 was preliminary evidence of higher TEWL in the AZD4017 group by +1% to 56% (mean +26%) 190 relative to placebo (Figure 3g, Table 2). By 168hr post-disruption, although median TEWL was still 191 higher in the AZD4017 group, all Cl included 0 (no difference) (Table 2). 192 Sensitivity analyses did not differ from the main conclusions (table S5, S8). 193 Epidermal thickness 194 Although median epidermal thickness was greater in the AZD4017 group, consistent with proof-of-195 concept, all CIs included 0 (no difference) (Table 2). The 90% CI indicated that median skin thickness 196 could be between 8% thinner to 26% thicker in the AZD4017 group relative to placebo. 197 Skin hydration 198 Although the medians suggested better hydration in the AZD4017 group, consistent with proof-of-199 concept, the 90% CI indicated median hydration could be anywhere between 7% lower and 37% 200 higher in those receiving AZD4017; all CIs included 0 (Table 2). 201 Sudomotor function 202 Across all sites, sudomotor function was equivocal as an effect in a particular direction; all CI 203 included 0 (Table 2). This was also true when the results were averaged across hands and feet 204 separately. The 75% and 80% CIs excluded 0 in the left hand (but not the right) with 80% CI 205 indicating between 2% and 36% greater function. 206 Sensitivity analyses indicated at 75% CI the possibility of between 1% and 13% lower sudomotor 207 function in feet and in those taking AZD4017 relative to placebo. 208 Correlations between compliance and efficacy outcomes 209 Several outcome measures displayed preliminary evidence of an association with compliance (absolute rho>=0.3) including negative associations with 11β-HSD1 activity by ELISA and 210 211 [THF+alloTHF]/THE ratios and positive associations with TEWL and skin hydration (table S11). 212 However, given the narrow range of compliance variability (and overall high compliance), these 213 putative associations should be interpreted with caution. 214 Additional sensitivity analyses of primary and secondary variables 215 Sensitivity analyses using available case (Table S9) and last observation carried forward (Table S10) 216 as alternative methods of handling missing data did not yield results that differed substantially from 217 the results of the main analyses, unless already highlighted above.

218 Safety 219 Biopsy and ECG 220 Biopsy sites did not raise any clinical concerns and all were found to pass a physical inspection. No 221 incidents of infection were observed. Participants did not report any pain or discomfort from the 222 biopsies, which all healed relatively well. 223 No clinically meaningful ECG anomalies were found in any patients remaining in the trial at day 42 224 (placebo n=13; AZD4017 n=14). 225 Longitudinal laboratory safety data 226 The 90% CI for the (baseline value, age, sex and baseline HbA1c) adjusted difference between 227 treatment groups indicated there was preliminary evidence that in the AZD4017 group relative to 228 placebo (Table 3): dehydroepiandrosterone sulphate (DHEAS) was higher at days 7, 28, 35 & 42 229 (Figure 4a), cholesterol was lower at days 7, 28 and 35 (Figure 4b), high density lipoprotein (HDL) 230 was lower at day 35 (Figure 4c) and systolic blood pressure (BP) was lower at day 28 (Figure 4d). 231 Mean corpuscular Hb (Figure 4e) and potassium (Figure 4f) were lower at day 7, sodium was lower 232 at day 42 (Figure 4g), creatinine was higher at day 7 (Figure 4h) and free thyroxine was higher at day 233 42 (Figure 4i). Most of these apparent differences were small in magnitude. For all except sodium, 234 potassium and free thyroxine, the adjusted difference at day 42, 7 days after the end of treatment, 235 was smaller than at day 35. 236 The remaining continuous safety variables did not show any preliminary differences between 237 AZD4017 and placebo in this study, although this may have been due to the small sample size and 238 relatively short treatment duration (Table 3). Unadjusted estimates (Table S12) were similar, although platelets were higher in AZD at each visit, values were already higher at baseline in this 239 240 group. Unadjusted and adjusted changes from baseline are presented for all laboratory safety 241 variables in Tables S13 and S14 respectively. 242 Although there were several values in each treatment group that were above or below accepted 243 clinical normal limits (Table S15), there were relatively few laboratory findings that were sufficient 244 cause for concern to warrant further investigation or intervention by the study team, and none 245 resulted in withdrawal from IMP. 246 Adverse events 247 There were a total of 37 adverse events (AE) (placebo n=13; AZD4017 n=24); counting recurring 248 instances of the same AE within a patient just once, there were 29 unique AE (placebo n=13; 249 AZD4017 n=16) (Table 4). The majority of AE were gastrointestinal, nervous system or respiratory, 250 and the majority were of mild severity (n=26), with only 3 of moderate severity and none of greater 251 severity. None of the 29 unique AE were considered probably or definitely study drug related, most 252 were deemed possibly related (n=20) or unlikely to be relate (n=8). AE were broadly balanced across 253 the treatment arms, although all three of the moderately severe events occurred in the AZD4017 254 group.

256

257

258

259

260

261262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

**Future study power estimation** Based on the power calculations from the current trial (table \$16), we anticipate that n=100-150 per arm should suffice to detect a difference of 20% or more relative to placebo for all outcome measures. **Discussion** Our double-blind, randomised, placebo-controlled, parallel clinical trial provides preliminary evidence that wounds were 12-85% (mean 48%) smaller and skin integrity was 7-91% (mean 43%) stronger in patients with type 2 diabetes mellitus following 11β-HSD1 inhibition. This represents a major advance in the development of  $11\beta$ -HSD1 inhibitors as a novel therapy for diabetic ulcers. Studies had previously demonstrated effective 11β-HSD1 inhibition in mouse skin (19, 23), but this had not been explored in humans. Our primary outcome measure failed to evidence 11β-HSD1 inhibition in skin. However, preliminary proof-of-concept was demonstrated though a reduction in [THF+alloTHF]/THE ratios (the gold-standard measure of systemic 11β-HSD1 activity) and elevated DHEAS consistent with other selective 11β-HSD1 inhibitor trials, including AZD4017 (34, 36-39). As anticipated,  $11\beta$ -HSD2 activity was unaffected (40, 41). The lack of peripheral inhibition was not due to a lack of exposure in situ as skin biopsy AZD4017 correlated with plasma levels, albeit at lower concentrations. However, a loss of efficacy ex vivo (lower target affinity when removed from much higher in situ circulating AZD4017 levels) or insufficient assay sensitivity (mean baseline 11β-HSD1 activity was relatively low) may explain this finding. Our secondary outcomes offer a series of novel insights into the effects of 11β-HSD1 inhibition on skin function. OCT is a validated method for non-invasive assessment of wound healing (42) and our study is the first application of this method in a randomised controlled trial. Our preliminary finding of improved wound healing at day 2 post-biopsy after less than two days' AZD4017 treatment is very promising. More so, given that overall healing in this cohort was relatively normal and the diabetes relatively well-managed. Evidence indicative of improved healing by AZD4017 was obtained after just two days of treatment and the preliminary estimates of effect size were greater after 30 days treatment. The fact that all CI included considerable improvements relative to placebo, and this was finding was repeatable in the two separate biopsies, provides good justification for progressing to a larger trial. This novel human data is consistent with the known deleterious effects of GC on wound healing (43) and with pre-clinical evidence of improved healing by  $11\beta$ -HSD1 inhibition in animal models of stress, obesity, GC excess and ageing from our group and others (19, 23-25). A recent study in db/db mice also reported increased 11β-HSD1 activity during wound healing compared to wild-type mice, although this remains to be explored in humans (44). By day 7 post-wounding, there was no preliminary evidence of an effect. However, this may have been limited by measurement of maximal clot depth, rather than volume, which should be addressed in future studies. Further, no granulation tissue was detectable at this time point, consistent with normal progression of healing. To strengthen the case for potential skin benefits of AZD4017, we also found preliminary evidence that AZD4017 may increase epidermal integrity, an improvement comparable to that of young vs. aged skin (45). This is supported by studies demonstrating reduced skin integrity following human psychological stress (46) or exogenous GC treatment (47). In contrast, we previously found increased

epidermal integrity in mice treated with oral corticosterone which was reversed by  $11\beta$ -HSD1

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

inhibition (23), suggesting epidermal integrity regulation by endogenous GC may be opposed in humans and mouse, highlighting the importance of our findings. Provisional evidence of a modest impairment in epidermal barrier function and recovery by AZD4017 was also observed in our study. GC are known to both impair and promote epidermal barrier function, the former predominantly with exogenous GC treatment (47-49) and the latter following endogenous GC excess (50). Our results indicate for the first time that endogenous cortisol also promotes epidermal barrier function via 11β-HSD1 in humans. GC have been shown to impair healing through repression of epidermal growth factor signalling that inhibits keratinocyte re-epithelialisation (essential for wound repair) whilst concomitantly promoting keratinocyte differentiation to promote barrier function (11). Our differential findings of improved wound healing and impaired barrier function by AZD4017 are in agreement, although barrier impairment was more modest. However, future trials exploring possible benefits of 11β-HSD1 inhibition on wound healing should monitor the epidermal barrier, particularly in patients with a compromised function e.g. atopic dermatitis. Peripheral neuropathy is a serious complication in diabetes. To safeguard against any possible detrimental effects on nerve function, sudomotor analysis was conducted (51). Nerve function was unaffected by AZD4017 overall and in the hands. At the lowest level of confidence, a modest impairment was noted in the feet and therefore, monitoring of nerve function should be included in future trials to rule out any adverse effects. In this relatively short, preliminary study, there were no significant safety concerns. Overall, eGFR and other laboratory safety outcomes gave no evidence of a detrimental effect. Indeed conversely, we found evidence of improvements in some "metabolic" traits, notably high density lipoprotein, cholesterol and systolic blood pressure in the AZD4017 arm which were not present at baseline or after 7 days treatment washout (and despite ongoing treatment for these conditions). These improvements are consistent with results from other selective  $11\beta$ -HSD1 inhibitor trials (33-36). Importantly, cardiovascular disease markers are a strong predictor of ulcer occurrence, healing, complications and recurrence (52, 53). Through alleviating cardiovascular disease burden, oral 11β-HSD1 inhibitors could also reduce ulcer recurrence in high risk patients, but this will require further clinical investigation with long-term  $11\beta$ -HSD1 inhibitor therapy. Concomitant medication was not formally captured in this trial and based on our findings, warrants monitoring in future studies. The use of wounds induced by biopsy, rather than active diabetic ulcers, was a key limitation of our study design. However, this was necessary to ensure AZD4017 did not raise any safety concerns in acute wounds and patients with relatively well-managed diabetes before progression to patients with more severe disease. The small sample size and lack of inferential testing, whilst recommended for pilot trials, require all putative findings presented here to be confirmed in fully-powered trials. It is likely that these would have greater resources to support recruitment, which, although target sample size was achieved, was also a limitation. Our findings make a strong case for a future study in patients with active ulcers where the primary outcome should be an established measure of ulcer healing. Given that approximately 5% of patients with type 2 diabetes have a diabetic foot ulcer, a future confirmatory trial will likely be multi-centre.

10

337

338

339

344

345

347

348

349

353

354

355

356

359

362

365

366

367

369

Stratification of randomisation by key variables known to affect 11β-HSD1 function (e.g. age) and wound healing (e.g. infection / ulcer size at presentation) is also advisable. Between-group differences were strongest following 28 days of AZD4017 treatment. Therefore, a future study schedule could be simplified and coordinated with routine appointments to improve recruitment. 340 Although requiring confirmation, improvements in healing, skin integrity and metabolic risk factors 341 of ulcer recurrence hold promise for 11β-HSD1 as a novel therapeutic target in wound repair. A fully-342 powered clinical trial in patients with active ulcers and type 2 diabetes mellitus is now warranted. 343 **Materials and Methods** The final approved trial Protocol v2.0 24th October 2018 is provided in Appendix 2. **Study Design** 346 This was a randomised, double-blind and parallel group, placebo-controlled, phase II pilot trial in patients with T2DM. Participants were recruited between 28<sup>th</sup> March 2018 and 23<sup>rd</sup> January 2019 (first to last randomised participant telephone invitations) with last participant last follow-up (telephone discharge) on 3<sup>rd</sup> April 2019. A total of 28 participants (22 male, 6 female) were randomised and 27 completed the 35 day oral AZD4017 or placebo treatment. For study design 350 351 details, please refer to section 5 of Appendix 2. 352 Selection of sample size Published guidance for pilot studies recommended a sample size of 12 participants per arm completing the protocol (54). To ensure this minimum number completed the protocol, the study aimed to randomise 15 per arm to allow for 20% drop-out. Please refer to section 13.9 in Appendix 2 for details. 357 **Consent, Ethical Approval and Oversight** 358 Informed consent was obtained after the nature and possible consequences of the study had been explained. Full ethical approval was acquired prior to onset of recruitment from North West Greater 360 Manchester Central Research Ethics Committee 17/NW/0283. 361 Data monitoring was carried out during the trial by the study management team and the sponsor. Independent oversight of the study including interim safety monitoring was conducted by an 363 Independent Data Monitoring and Ethics Committee. 364 Randomisation and blinding The randomisation process is described in section 6.4.3 of Appendix 1. Blinding procedures included participants and the study team being blinded to the randomisation process, mitigation of accidental unblinding, semi-blind interim safety analyses and independent Data Monitoring and Ethics 368 Committee oversight. Dosing compliance was monitored by self-reported completion of diary cards and by counting the number of tablets remaining at each study visit (see Materials and Methods). 370 Further detail is provided in section 7 of Appendix 2.

#### Treatments and withdrawal criteria

- 372 Participants received either oral AZD4017 (400mg) or matched oral placebo, twice daily for 35 days.
- 373 For full treatment and compliance details please see section 8 of Appendix 2. AZD4017 withdrawal
- 374 criteria are detailed in section 6.5 of Appendix 2.

#### Study endpoints

371

375

395

- The primary endpoint was 24hr 11β-HSD1 activity in skin (efficacy) at baseline and day 28. Secondary
- 377 endpoints were systemic 11β-HSD1 activity at baseline and day 35 and AZD4017 quantification in
- 378 skin at day 28 and plasma at day 35 (to support efficacy), safety variables at baseline and days 7, 28
- and 35, blood pressure, blood safety variables, EGC and biopsy inspection at day 42, urinary cortisol
- 380 to cortisone metabolite analysis at baseline and day 35 (to assess systemic GC levels), skin function
- variables at baseline and days 2, 7, 28, 30 and 35 and feasibility variables at throughout the study.
- Further details are provided in sections 4, 9 and 10 of Appendix 2.

### 383 Statistical Methods

- A standalone statistical analysis plan (SAP) was developed and finalised prior to breaking of the blind
- and processing of primary outcome samples.
- 386 In this pilot study, the analysis was descriptive throughout and hence no specific inferential
- 387 hypotheses were formally tested. Analysis followed published recommendations which state that in
- 388 pilot trials the focus should be on descriptive statistics and estimation, using a range of confidence
- intervals (CIs) other than 95% confidence, and interpreting these with regards to the minimum
- 390 clinically important difference (MCID)(55). As MCIDs have not been established in this patient group
- 391 for the outcomes under investigation, we have converted the CI limits into % difference relative to
- 392 the mean or median in the placebo group as a guideline when reporting results. Analyses were
- conducted in Stata 16.1 (StataCorp 2019. College Station, TX). For further details please refer to
- 394 section 13 of Appendix 2 and Appendix 3.

### References and Notes

- C. K. Sen, G. M. Gordillo, S. Roy, R. Kirsner, L. Lambert, T. K. Hunt, F. Gottrup, G. C. Gurtner,
   M. T. Longaker, Human skin wounds: a major and snowballing threat to public health and
   the economy. Wound repair and regeneration: official publication of the Wound Healing
   Society [and] the European Tissue Repair Society 17, 763-771 (2009).
- F. Gottrup, J. Apelqvist, P. Price, G. European Wound Management Association Patient
   Outcome, Outcomes in controlled and comparative studies on non-healing wounds:
   recommendations to improve the quality of evidence in wound management. *Journal of wound care* 19, 237-268 (2010).
- 404 3. K. R. Vowden, P. Vowden, A survey of wound care provision within one English health care district. *Journal of tissue viability* **18**, 2-6 (2009).
- 406 4. K. Vowden, P. Vowden, J. Posnett, The resource costs of wound care in Bradford and
  407 Airedale primary care trust in the UK. *Journal of wound care* **18**, 93-94, 96-98, 100 passim
  408 (2009).
- N. Hex, C. Bartlett, D. Wright, M. Taylor, D. Varley, Estimating the current and future costs of
   Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and
   productivity costs. Diabetic medicine: a journal of the British Diabetic Association 29, 855 862 (2012).
- 413 6. J. R. Sowers, H. R. Lippman, Cushing's syndrome due to ectopic ACTH production: cutaneous manifestations. *Cutis* **36**, 351-352, 354 (1985).

- P. Autio, A. Oikarinen, J. Melkko, J. Risteli, L. Risteli, Systemic glucocorticoids decrease the synthesis of type I and type III collagen in human skin in vivo, whereas isotretinoin treatment has little effect. *The British journal of dermatology* **131**, 660-663 (1994).
- 418 8. V. P. Werth, A. M. Kligman, X. Shi, A. Pagnoni, Lack of correlation of skin thickness with bone density in patients receiving chronic glucocorticoid. *Archives of dermatological research* **290**, 388-393 (1998).
- 421 9. H. C. Korting, A. Unholzer, M. Schafer-Korting, I. Tausch, J. Gassmueller, K. H. Nietsch,
   422 Different skin thinning potential of equipotent medium-strength glucocorticoids. Skin pharmacology and applied skin physiology 15, 85-91 (2002).
- 424 10. P. Nuutinen, R. Riekki, M. Parikka, T. Salo, P. Autio, J. Risteli, A. Oikarinen, Modulation of collagen synthesis and mRNA by continuous and intermittent use of topical hydrocortisone in human skin. *The British journal of dermatology* **148**, 39-45 (2003).
- 427 11. B. Lee, C. Vouthounis, O. Stojadinovic, H. Brem, M. Im, M. Tomic-Canic, From an
   428 enhanceosome to a repressosome: molecular antagonism between glucocorticoids and EGF
   429 leads to inhibition of wound healing. *Journal of molecular biology* 345, 1083-1097 (2005).
- 430 12. S. Schoepe, H. Schacke, E. May, K. Asadullah, Glucocorticoid therapy-induced skin atrophy.

  431 Experimental dermatology 15, 406-420 (2006).
- 432 13. K. M. Aberg, K. A. Radek, E. H. Choi, D. K. Kim, M. Demerjian, M. Hupe, J. Kerbleski, R. L.
   433 Gallo, T. Ganz, T. Mauro, K. R. Feingold, P. M. Elias, Psychological stress downregulates
   434 epidermal antimicrobial peptide expression and increases severity of cutaneous infections in
   435 mice. The Journal of clinical investigation 117, 3339-3349 (2007).
- 436 14. S. E. Lee, J. M. Kim, M. K. Jeong, C. C. Zouboulis, S. H. Lee, 11beta-hydroxysteroid 437 dehydrogenase type 1 is expressed in human sebaceous glands and regulates glucocorticoid-438 induced lipid synthesis and toll-like receptor 2 expression in SZ95 sebocytes. *The British* 439 *journal of dermatology* **168**, 47-55 (2013).
- 440 15. R. G. Albuquerque, M. A. Rocha, E. Bagatin, S. Tufik, M. L. Andersen, Could adult female acne be associated with modern life? *Archives of dermatological research* **306**, 683-688 (2014).
- 442 16. S. Roy, S. Khanna, P. E. Yeh, C. Rink, W. B. Malarkey, J. Kiecolt-Glaser, B. Laskowski, R. Glaser, C. K. Sen, Wound site neutrophil transcriptome in response to psychological stress in young men. *Gene expression* **12**, 273-287 (2005).
- 445 17. P. T. Marucha, J. K. Kiecolt-Glaser, M. Favagehi, Mucosal wound healing is impaired by examination stress. *Psychosomatic medicine* **60**, 362-365 (1998).
- S. A. Morgan, E. L. McCabe, L. L. Gathercole, Z. K. Hassan-Smith, D. P. Larner, I. J. Bujalska, P.
   M. Stewart, J. W. Tomlinson, G. G. Lavery, 11beta-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess. *Proceedings of the National Academy of Sciences of the United States of America* 111, E2482-2491 (2014).
- 451 19. A. Tiganescu, A. A. Tahrani, S. A. Morgan, M. Otranto, A. Desmouliere, L. Abrahams, Z.
   452 Hassan-Smith, E. A. Walker, E. H. Rabbitt, M. S. Cooper, K. Amrein, G. G. Lavery, P. M.
   453 Stewart, 11beta-Hydroxysteroid dehydrogenase blockade prevents age-induced skin
   454 structure and function defects. *The Journal of clinical investigation* 123, 3051-3060 (2013).
- 455 20. A. Tiganescu, E. A. Walker, R. S. Hardy, A. E. Mayes, P. M. Stewart, Localization, age- and site-456 dependent expression, and regulation of 11beta-hydroxysteroid dehydrogenase type 1 in 457 skin. *The Journal of investigative dermatology* **131**, 30-36 (2011).
- 458 21. G. Hirasawa, H. Sasano, K. Takahashi, K. Fukushima, T. Suzuki, N. Hiwatashi, T. Toyota, Z. S. Krozowski, H. Nagura, Colocalization of 11 beta-hydroxysteroid dehydrogenase type II and mineralocorticoid receptor in human epithelia. *The Journal of clinical endocrinology and metabolism* **82**, 3859-3863 (1997).
- 462 22. A. Tiganescu, M. Hupe, Y. Uchida, T. Mauro, P. M. Elias, W. M. Holleran, Increased
   463 glucocorticoid activation during mouse skin wound healing. *The Journal of endocrinology* 464 221, 51-61 (2014).

- 465 23. A. Tiganescu, M. Hupe, Y. Uchida, T. Mauro, P. M. Elias, W. M. Holleran, Topical 11 beta-466 Hydroxysteroid Dehydrogenase Type 1 Inhibition Corrects Cutaneous Features of Systemic 467 Glucocorticoid Excess in Female Mice. *Endocrinology* **159**, 547-556 (2018).
- 468 24. M. Terao, H. Murota, A. Kimura, A. Kato, A. Ishikawa, K. Igawa, E. Miyoshi, I. Katayama, 11beta-Hydroxysteroid dehydrogenase-1 is a novel regulator of skin homeostasis and a candidate target for promoting tissue repair. *PloS one* **6**, e25039 (2011).
- J. K. Youm, K. Park, Y. Uchida, A. Chan, T. M. Mauro, W. M. Holleran, P. M. Elias, Local
   blockade of glucocorticoid activation reverses stress- and glucocorticoid-induced delays in
   cutaneous wound healing. Wound repair and regeneration: official publication of the
   Wound Healing Society [and] the European Tissue Repair Society 21, 715-722 (2013).
- 475 26. K. E. Chapman, A. E. Coutinho, Z. Zhang, T. Kipari, J. S. Savill, J. R. Seckl, Changing
   476 glucocorticoid action: 11beta-hydroxysteroid dehydrogenase type 1 in acute and chronic
   477 inflammation. *The Journal of steroid biochemistry and molecular biology* 137, 82-92 (2013).
- S. Itoi, M. Terao, H. Murota, I. Katayama, 11beta-Hydroxysteroid dehydrogenase 1
   contributes to the pro-inflammatory response of keratinocytes. *Biochemical and biophysical research communications* 440, 265-270 (2013).
- 481 28. I. D. Ignatova, R. M. Kostadinova, C. E. Goldring, A. R. Nawrocki, F. J. Frey, B. M. Frey, Tumor
   482 necrosis factor-alpha upregulates 11beta-hydroxysteroid dehydrogenase type 1 expression
   483 by CCAAT/enhancer binding protein-beta in HepG2 cells. *American journal of physiology*.
   484 *Endocrinology and metabolism* 296, E367-377 (2009).
- 485 29. M. S. Bitar, Glucocorticoid dynamics and impaired wound healing in diabetes mellitus. *The American journal of pathology* **152**, 547-554 (1998).
- 487 30. A. Steptoe, R. A. Hackett, A. I. Lazzarino, S. Bostock, R. La Marca, L. A. Carvalho, M. Hamer,
  488 Disruption of multisystem responses to stress in type 2 diabetes: Investigating the dynamics
  489 of allostatic load. *Proceedings of the National Academy of Sciences of the United States of*490 *America* **111**, 15693-15698 (2014).
- 491 31. K. Kaur, R. Hardy, M. M. Ahasan, M. Eijken, J. P. van Leeuwen, A. Filer, A. M. Thomas, K.
  492 Raza, C. D. Buckley, P. M. Stewart, E. H. Rabbitt, M. Hewison, M. S. Cooper, Synergistic
  493 induction of local glucocorticoid generation by inflammatory cytokines and glucocorticoids:
  494 implications for inflammation associated bone loss. *Annals of the rheumatic diseases* 69,
  495 1185-1190 (2010).
- 496 32. L. L. Gathercole, G. G. Lavery, S. A. Morgan, M. S. Cooper, A. J. Sinclair, J. W. Tomlinson, P. M.
   497 Stewart, 11beta-Hydroxysteroid dehydrogenase 1: translational and therapeutic aspects.
   498 Endocrine reviews 34, 525-555 (2013).
- J. Rosenstock, S. Banarer, V. A. Fonseca, S. E. Inzucchi, W. Sun, W. Yao, G. Hollis, R. Flores, R. Levy, W. V. Williams, J. R. Seckl, R. Huber, I. P. Investigators, The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. *Diabetes care* 33, 1516-1522 (2010).
- P. U. Feig, S. Shah, A. Hermanowski-Vosatka, D. Plotkin, M. S. Springer, S. Donahue, C. Thach,
   E. J. Klein, E. Lai, K. D. Kaufman, Effects of an 11beta-hydroxysteroid dehydrogenase type 1
   inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome.
   Diabetes, obesity & metabolism 13, 498-504 (2011).
- 508 35. S. Shah, A. Hermanowski-Vosatka, K. Gibson, R. A. Ruck, G. Jia, J. Zhang, P. M. Hwang, N. W. Ryan, R. B. Langdon, P. U. Feig, Efficacy and safety of the selective 11beta-HSD-1 inhibitors 510 MK-0736 and MK-0916 in overweight and obese patients with hypertension. *Journal of the American Society of Hypertension : JASH* 5, 166-176 (2011).
- 512 36. R. S. Hardy, H. Botfield, K. Markey, J. L. Mitchell, Z. Alimajstorovic, C. S. J. Westgate, M. Sagmeister, R. J. Fairclough, R. S. Ottridge, A. Yiangou, K. H. Storbeck, A. E. Taylor, L. C. Cillian, W. Arlt, B. M. Stowart, L. W. Tamlingen, S. R. Mellen, C. C. Lavor, A. L. Singlein.

514 Gilligan, W. Arlt, P. M. Stewart, J. W. Tomlinson, S. P. Mollan, G. G. Lavery, A. J. Sinclair,

- 515 11betaHSD1 Inhibition with AZD4017 Improves Lipid Profiles and Lean Muscle Mass in Idiopathic Intracranial Hypertension. *J Clin Endocrinol Metab* **106**, 174-187 (2021).
- 517 37. D. Schwab, C. Sturm, A. Portron, S. Fuerst-Recktenwald, D. Hainzl, P. Jordan, W. C. Stewart, M. E. Tepedino, H. DuBiner, Oral administration of the 11beta-hydroxysteroid-dehydrogenase type 1 inhibitor RO5093151 to patients with glaucoma: an adaptive, randomised, placebo-controlled clinical study. *BMJ Open Ophthalmol* 1, e000063 (2017).
- 38. T. Heise, L. Morrow, M. Hompesch, H. U. Haring, C. Kapitza, M. Abt, M. Ramsauer, M. C.
   Magnone, S. Fuerst-Recktenwald, Safety, efficacy and weight effect of two 11beta-HSD1 inhibitors in metformin-treated patients with type 2 diabetes. *Diabetes, obesity & metabolism* 16, 1070-1077 (2014).
- S. Freude, T. Heise, H. J. Woerle, A. Jungnik, T. Rauch, B. Hamilton, C. Scholch, F. Huang, U.
   Graefe-Mody, Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective
   11beta-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver and adipose
   tissue 11beta-HSD1 inhibition after acute and multiple administrations over 2 weeks.
   Diabetes Obes Metab 18, 483-490 (2016).
- M. S. Sagmeister, A. E. Taylor, A. Fenton, N. A. Wall, D. Chanouzas, P. G. Nightingale, C. J.
   Ferro, W. Arlt, P. Cockwell, R. S. Hardy, L. Harper, Glucocorticoid activation by 11beta-hydroxysteroid dehydrogenase enzymes in relation to inflammation and glycaemic control in chronic kidney disease: A cross-sectional study. *Clinical endocrinology* 90, 241-249 (2019).
- 534 41. M. Palermo, C. H. Shackleton, F. Mantero, P. M. Stewart, Urinary free cortisone and the 535 assessment of 11 beta-hydroxysteroid dehydrogenase activity in man. *Clinical endocrinology* 536 **45**, 605-611 (1996).
- 537 42. N. S. Greaves, B. Benatar, S. Whiteside, T. Alonso-Rasgado, M. Baguneid, A. Bayat, Optical coherence tomography: a reliable alternative to invasive histological assessment of acute wound healing in human skin? *Br J Dermatol* **170**, 840-850 (2014).
- 540 43. E. Harris, A. Tiganescu, S. Tubeuf, S. L. Mackie, The prediction and monitoring of toxicity 541 associated with long-term systemic glucocorticoid therapy. *Current rheumatology reports* 542 **17**, 513 (2015).
- 543 44. C. B. Brazel, J. C. Simon, J. P. Tuckermann, A. Saalbach, Inhibition of 11beta-HSD1 Expression by Insulin in Skin: Impact for Diabetic Wound Healing. *J Clin Med* **9**, (2020).
- R. Ghadially, B. E. Brown, S. M. Sequeira-Martin, K. R. Feingold, P. M. Elias, The aged
   epidermal permeability barrier. Structural, functional, and lipid biochemical abnormalities in
   humans and a senescent murine model. *The Journal of clinical investigation* 95, 2281-2290
   (1995).
- 549 46. S. J. Choe, D. Kim, E. J. Kim, J. S. Ahn, E. J. Choi, E. D. Son, T. R. Lee, E. H. Choi, Psychological
   550 Stress Deteriorates Skin Barrier Function by Activating 11beta-Hydroxysteroid
   551 Dehydrogenase 1 and the HPA Axis. Sci Rep 8, 6334 (2018).
- J. S. Kao, J. W. Fluhr, M. Q. Man, A. J. Fowler, J. P. Hachem, D. Crumrine, S. K. Ahn, B. E.
   Brown, P. M. Elias, K. R. Feingold, Short-term glucocorticoid treatment compromises both
   permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal
   lipid synthesis accounts for functional abnormalities. *The Journal of investigative* dermatology 120, 456-464 (2003).
- 557 48. L. Kolbe, A. M. Kligman, V. Schreiner, T. Stoudemayer, Corticosteroid-induced atrophy and 558 barrier impairment measured by non-invasive methods in human skin. *Skin research and* 559 *technology : official journal of International Society for Bioengineering and the Skin* **7**, 73-77 560 (2001).
- 561 49. S. K. Ahn, H. N. Bak, B. D. Park, Y. H. Kim, J. K. Youm, E. H. Choi, S. P. Hong, S. H. Lee, Effects
   562 of a multilamellar emulsion on glucocorticoid-induced epidermal atrophy and barrier
   563 impairment. *The Journal of dermatology* 33, 80-90 (2006).
- 564 50. T. K. Lin, M. Q. Man, J. L. Santiago, T. C. Scharschmidt, M. Hupe, G. Martin-Ezquerra, J. K. Youm, Y. Zhai, C. Trullas, K. R. Feingold, P. M. Elias, Paradoxical benefits of psychological

- stress in inflammatory dermatoses models are glucocorticoid mediated. *The Journal of investigative dermatology* **134**, 2890-2897 (2014).
- A. I. Vinik, M. L. Nevoret, C. Casellini, The New Age of Sudomotor Function Testing: A
   Sensitive and Specific Biomarker for Diagnosis, Estimation of Severity, Monitoring
   Progression, and Regression in Response to Intervention. Frontiers in endocrinology 6, 94
   (2015).
- 572 52. D. G. Armstrong, A. J. M. Boulton, S. A. Bus, Diabetic Foot Ulcers and Their Recurrence. *N Engl J Med* **376**, 2367-2375 (2017).
- 574 53. M. J. Young, J. E. McCardle, L. E. Randall, J. I. Barclay, Improved survival of diabetic foot ulcer 575 patients 1995-2008: possible impact of aggressive cardiovascular risk management. *Diabetes* 576 *Care* 31, 2143-2147 (2008).
- 577 54. S. A. Julious, Sample size of 12 per group rule of thumb for a pilot study. *Pharm Stat* **4**, 287-578 291 (2005).
- 579 55. E. C. Lee, A. L. Whitehead, R. M. Jacques, S. A. Julious, The statistical interpretation of pilot trials: should significance thresholds be reconsidered? *Bmc Med Res Methodol* **14**, (2014).

## **Acknowledgements**

581

582

- Funding: This work was supported by an MRC Confidence in Concept Award (MC PC 15046) to Ana
- 584 Tiganescu, the NIHR Leeds Biomedical Research Centre, NIHR Leeds In vitro Diagnostic Evidence Co-
- operative and NIHR Senior Investigator Award to Paul Stewart (NF-SI-0514-10090). Author
- 586 contributions: Ramzi Ajjan: Conceptualization, Methodology, Investigation, Writing Review &
- 587 Editing, Resources, Supervision (joint), Elizabeth Hensor: Software, Formal analysis, Data Curation,
- 588 Writing Review & Editing, Visualization, Kave Shams: Investigation, Francesco Del Galdo:
- Investigation, Afroze Abbas: Investigation, Janet Woods: Investigation, Ann Morgan: Supervision
- 590 (supporting), Writing Review & Editing, Paul M Stewart: Conceptualization, Funding acquisition,
- 591 Writing Review & Editing, Rebecca Fairclough: Resources, Supervision (supporting), Lorraine
- Webber: Resources, Supervision (supporting), Lindsay Pegg: Resources, Supervision (supporting),
- 593 Adrian Freeman: Writing Review & Editing, Resources, Supervision (supporting), Angela E Taylor:
- 594 Investigation, Wiebke Arlt: Methodology, Abd Tahrani: Conceptualization, Writing Review &
- 595 Editing, David Russell: Investigation, Supervision (supporting) and Ana Tiganescu: Conceptualization
- (lead), Funding acquisition (lead), Investigation (lead), Methodology (lead), Project administration
- 597 (lead), Supervision (joint), Validation, Writing Original Draft, Writing Review & Editing. Competing
- interests: nothing to disclose. Data and materials availability: All data associated with this study are
- available in the main text or the supplementary materials. **Trial registration:** International Standard
- Randomised Controlled Trial Number 74621291 www.isrctn.com/ISRCTN74621291. ClinicalTrials.gov
- 601 Identifier: NCT03313297 https://clinicaltrials.gov/ct2/show/NCT03313297.
- 602 This paper presents independent research supported by the National Institute for Health Research
- 603 (NIHR) Leeds Biomedical Research Centre (BRC). The views expressed are those of the authors and
- not necessarily those of the NIHR or the Department of Health and Social Care.

## Figure Captions

605

## 606 Figure 1 CONSORT flow diagram

- Progress, from screening through to study completion, of participants in the double-blind
- 608 randomised placebo-controlled trial testing a 35 day oral AZD4017 treatment versus placebo in

609 adults with type 2 diabetes. A total of 300 prospective participants were screened. Eight of the 36 610 individuals enrolled in the study were not randomised owing to not meeting eligibility criteria. 27 out 611 of 28 participants who were randomised completed the study. 612 Figure 2 Efficacy outcome measures Adjusted differences between placebo (PCB) and AZD4017 (AZD) groups in absolute values of 613 614 primary and secondary efficacy outcomes in the full analysis set. Box plots of observed values (left 615 panel) and adjusted differences between medians estimated in imputed data (right panel) are 616 presented. Solid lines indicate no difference between groups (=0). Dotted lines indicate 20% 617 improvement relative to the median PCB (not applicable to F/E ratio). 618 Figure 3 Skin outcome measures 619 (a-b, d-g) Adjusted differences between placebo (PCB) and AZD4017 (AZD) groups in absolute values 620 of secondary efficacy outcomes in the full analysis set. Error bar plots of observed values (indicating 621 90% CIs; left panel) and adjusted differences between means estimated in imputed data (right panel) 622 are presented. TEWL and integrity readings were log-transformed prior to analysis therefore 623 geometric means and ratios have been provided for these variables. Solid lines indicate no 624 difference between groups (=0 for WH, =1 for TEWL and integrity). Dotted lines indicate 20% 625 improvement relative to the mean in PCB. 626 (c)Representative wound healing OCT images at day 2 (2 days post-biopsy and 2 days of AZD4017 627 treatment). Maximal early granulation tissue width (arrow) was measured for participants treated 628 with placebo (left panel) or AZD4017 (right panel). Wide dashes indicate dermal-epidermal junction. 629 Epidermis = e. Dermis = d. Granulation tissue = gt Scale bar = 250μm. 630 Figure 4 Safety 631 Displays of longitudinal laboratory safety data. Population: Safety set. ULN = upper limit of normal; 632 LLN = lower limit of normal (where applicable). 633 **Table Captions** 634 Table 1 635 Baseline demographics, primary and secondary efficacy variables, laboratory safety variables. 636 Population: Full analysis set. 637 Table 2 638 Primary and secondary efficacy outcomes; adjusted differences between treatment groups. 639 Population: Full analysis set. Multiple imputation was used to address missing data. Due to issues 640 with the data distributions, for all variables except TEWL, integrity, wound diameter & depth, 641 median regression was used to estimate confidence intervals around differences between the 642 groups. For TEWL, integrity, wound depth and diameter, linear regression was used. TEWL and 643 integrity measurements were log-transformed prior to analysis; differences have been expressed as 644 ratios of geometric means (AZD:PCB). For each variable, the comparison was adjusted for baseline 645 value of the variable (not applicable to wound diameter & depth), age, sex and baseline HbA1c. All 646 TEWL readings were adjusted using TEWL baseline at day 0. Between group differences were not 647 calculated for biopsy and plasma AZD4017 because available PCB values did not vary, all were below 648 the detection limit.

Table 3 Longitudinal laboratory safety variables; adjusted differences between treatment groups. Population: Safety set. All point estimates and confidence intervals estimated via linear regression. Table 4 653 Adverse event summary. Population: Safety set. **Supplementary Material** Table S1. Full descriptive data for primary and secondary efficacy variables. Population: Full analysis set. Table S2. Full descriptive data for laboratory safety variables. Population: Safety set. Table S3. IMP (placebo or AZD4017) compliance. Population: Full analysis set. Figure S1. Correlation between AZD4017 levels in the biopsy taken at day 28 and in plasma taken at 660 day 35. Population: Full analysis set (AZD4017 group only). Table S4. Primary and secondary efficacy outcomes; unadjusted differences in final values between treatment groups. Population: Full analysis set. Multiple imputation was used to address missing data. Due to issues with the data distributions, for all variables except TEWL, integrity, wound diameter & depth, median regression was used to estimate confidence intervals around differences between the groups. For TEWL, integrity, wound depth and diameter, linear regression was used. TEWL and integrity measurements were log-transformed prior to analysis; differences have been expressed as ratios of geometric means (AZD:PCB). Table S5. Sensitivity analysis of primary and secondary efficacy outcomes re-imputed after QC fails and outliers removed. Population: Full analysis set. Sensitivity analysis. Data were re-imputed after deleting two baseline radioassays which failed QC and one outlying ELISA assay result at day 28, TEWL readings that were potentially unreliable due to high temperatures and TEWL and WH measures which were collected earlier than scheduled. For each variable, the comparison was adjusted for baseline value of the variable (where applicable; not applicable to wound diameter & depth), age, sex and baseline HbA1c. All TEWL readings were adjusted using TEWL baseline at day 0. Figure S2. Correlation between the different methods of assessing 24hr 11bHSD1 activity (% conv/24hr). Population: Full analysis set. Table S6: Unadjusted differences in changes from baseline in primary and secondary efficacy outcomes. Population: Full analysis set. Multiple imputation was used to address missing data. Due to issues with the data distributions, for all variables except TEWL & integrity, median regression was 680 used to estimate confidence intervals around differences between the groups. For TEWL & integrity, linear regression was used. TEWL and integrity measurements were log-transformed prior to analysis. For these variables changes from baseline have been expressed as ratios of follow-up measurements to baseline values; between-group differences have been expressed as ratios of geometric means (AZD:PCB).

649

650

651

652

654

655

656

657

658

659

661

662 663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

681

682

683

684

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705 706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

Table S7: Adjusted differences in changes from baseline in primary and secondary efficacy outcomes. Population: Full analysis set. Multiple imputation was used to address missing data. Due to issues with the data distributions, for all variables except TEWL & integrity, median regression was used to estimate confidence intervals around differences between the groups. For TEWL & integrity, linear regression was used. TEWL and integrity measurements were log-transformed prior to analysis. For these variables changes from baseline have been expressed as ratios of follow-up measurements to baseline values; between-group differences have been expressed as ratios of geometric means (AZD: PCB). For each variable, the comparison was adjusted for baseline value of the variable, age, sex and baseline HbA1c. Table S8: Sensitivity analysis of trans-epidermal water loss (TEWL) adjusting for exact timing of postdisruption measurements. Population: Full analysis set. Analysis models included exact measurement times to account for variation in timings; results have been provided for a) data imputed including all observed values and b) data re-imputed after deleting TEWL readings that were potentially unreliable due to high temperatures. Linear mixed models were used to model post-baseline TEWL readings (within each set) as a function of time since disruption. Quadratic functions were added to allow for nonlinear change over time. Baseline values and changes over time were permitted to vary between patients. TEWL measurements were log-transformed prior to analysis; differences have been expressed as ratios of geometric means (AZD:PCB). For each variable, the comparison was adjusted for baseline (day 0, hour 0) TEWL, age, sex and baseline HbA1c. Table S9. Sensitivity analysis of primary and secondary efficacy outcomes in available case data. Population: Full analysis set. Due to issues with the data distributions, for all variables except TEWL, integrity, wound diameter & depth, quantile (median) regression was used to obtain point estimates and confidence intervals for differences between groups. For TEWL, integrity, wound depth and diameter, linear regression was used. TEWL and integrity measurements were log-transformed prior to analysis; differences have been expressed as ratios of geometric means (AZD:PBO). For each variable, the comparison was adjusted for baseline value of the variable (where applicable; not applicable to wound diameter & depth), age, sex and baseline HbA1c. All TEWL readings were adjusted using TEWL baseline at day 0. Table S10. Sensitivity analysis of primary and secondary efficacy outcomes using last observation carried forward. Population: Full analysis set. Due to issues with the data distributions, for all variables except TEWL, integrity, wound diameter & depth, quantile (median) regression was used to obtain point estimates and confidence intervals for differences between groups. For TEWL, integrity, wound depth and diameter, linear regression was used. TEWL and integrity measurements were logtransformed prior to analysis; differences have been expressed as ratios of geometric means (AZD:PBO). For each variable, the comparison was adjusted for baseline value of the variable (where applicable; not applicable to wound diameter & depth), age, sex and baseline HbA1c. All TEWL readings were adjusted using TEWL baseline at day 0. Note that day 0 TEWL measurements were missed in error for 1 patient therefore data could only be carried forward for 27 patients. Table S11. Correlations between AZD4017 compliance and efficacy outcomes. Population: Full analysis set (AZD group only). Absolute rho values >/= 0.3 were considered preliminary evidence of association. Sensitivity analysis excluded baseline radioimmunoassay samples that failed QC, an outlying ELISA assay result at day 28, TEWL readings recorded on very hot days, and results that

outlying ELISA assay result at day 28, TEWL readings recorded on very hot days, and results that

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744


745

746


747


were recorded 1 day earlier than planned, prior to imputation. Note that not all of these issues occurred in samples from the AZD group but could have altered imputed values for any incomplete variables. Table S12. Unadjusted differences in final values of longitudinal laboratory safety variables. Population: Safety set. Multiple imputation was used to address missing data. All point estimates and confidence intervals estimated via linear regression. Table \$13. Unadjusted differences in changes from baseline in longitudinal laboratory safety variables. Population: Safety set. Multiple imputation was used to address missing data. All point estimates and confidence intervals estimated via linear regression. Table S14. Adjusted differences in changes from baseline in longitudinal laboratory safety variables. Population: Safety set. Multiple imputation was used to address missing data. All point estimates and confidence intervals estimated via linear regression. Table S15. Longitudinal laboratory safety variables; absolute and relative frequencies of values below or above normal limits. Population: Safety set Table S16. Sample sizes for future trials. Based on estimates from available case data in full analysis set. At alpha=0.05 (5% significance), 1-Beta=0.90 (90% power), accounting for 10% drop-out, sample sizes for a range of substantive between-group differences are presented below. For TEWL and integrity variables, means and SDs are presented on the log scale. Note that for all variables, sample size has been based on mean and SD (and Pearson's r where applicable), as specified in the statistical analysis plan; issues with distributions for some variables may reduce the accuracy of these estimates. Sample sizes presented here should be considered preliminary.


Figure 1





# Figure 2
















Figure 3







PCB

PCB




Table 1: Baseline demographics, primary and secondary efficacy variables, laboratory safety variables.

Population: Full analysis set.

Variable	Summary	РСВ	AZD	Total N=28	
	-	N=14	N=14		
Age	Mean (SD), range	60.3 (13.4), 31.0 to 84.0	60.1 (14.5), 28.0 to 75.0	60.2 (13.7), 28.0 to 84.0	
Male	n/N (%)	12/14 (86)	10/14 (71)	22/28 (79)	
11bHSD1 activity radioassay (% conv/24hrs)	Median (Q1, Q3)	15.3 (11.6, 18.4)	10.7 (9.4, 17.4)	13.6 (9.8, 17.9)	
11bHSD1 activity ELISA (% conv/24hrs)	Median (Q1, Q3)	6.8 (5.5, 15.6)	6.4 (4.2, 8.5)	6.8 (4.8, 10.7)	
Sudomotor function Left Hand (micro S)	Median (Q1, Q3)	54.0 (47.0, 63.0)	57.5 (39.0, 71.0)	56.0 (46.5, 68.5)	
Sudomotor function Right Hand (micro S)	Median (Q1, Q3)	54.0 (47.0, 60.0)	56.5 (41.0, 67.0)	56.0 (45.5, 61.5)	
Sudomotor function Hands (micro S)	Median (Q1, Q3)	53.8 (48.0, 60.5)	56.8 (40.0 <i>,</i> 70.5)	56.8 (47.3, 65.0)	
Sudomotor function Left Foot (micro S)	Median (Q1, Q3)	65.5 (46.0 <i>,</i> 78.0)	79.0 (63.0, 84.0)	74.5 (57.0, 81.5)	
Sudomotor function Right Foot (micro S)	Median (Q1, Q3)	69.5 (48.0 <i>,</i> 79.0)	77.0 (69.0, 82.0)	74.0 (54.5 <i>,</i> 79.0)	
Sudomotor function Feet (micro S)	Median (Q1, Q3)	67.5 (44.5, 76.5)	78.0 (64.0, 83.5)	75.0 (55.8, 79.8)	
Sudomotor function Overall (micro S)	Median (Q1, Q3)	61.0 (46.8, 67.8)	66.6 (63.3, 71.3)	64.6 (50.3, 69.8)	
Skin hydration (A.U)	Median (Q1, Q3)	40.5 (34.5, 46.2)	40.4 (36.7, 45.5)	40.5 (36.1, 45.8)	
Epidermal thickness (micro m)	Median (Q1, Q3)	62.8 (54.5, 69.2)	65.7 (60.7, 69.3)	63.8 (58.4, 69.3)	
Cortisol (mcg/24h)	Median (Q1, Q3)	68.5 (40.0, 101.0)	75.5 (48.0, 84.0)	74.5 (47.5, 94.0)	
Urinary [THF+alloTHF]/THE ratio	Median (Q1, Q3)	1.0 (0.8, 1.2)	1.0 (0.8, 1.1)	1.0 (0.8, 1.1)	
Hour 0 TEWL (Set 1; Day 0)	Log scale Mean (SD), n	2.1 (0.4), n=14	2.2 (0.3), n=13	2.2 (0.4), n=27	
	Geometric Mean	8.2	9.1	8.6	
N tapes required for barrier disruption	Log scale Mean (SD), n	3.8 (0.4), n=14	3.9 (0.5), n=13	3.9 (0.4), n=27	
	Geometric Mean	44.5	50.5	47.5	
Body Mass Index (kg / m2)	Mean (SD)	33.67 (13.47)	35.05 (5.68)	34.36 (10.17)	
Waist-hip ratio	Mean (SD)	0.98 (0.08)	1.03 (0.08)	1.01 (0.08)	
Systolic blood pressure (mm Hg)	Mean (SD)	135.71 (21.01)	140.43 (12.02)	138.07 (16.97)	
Diastolic blood pressure (mm Hg)	Mean (SD)	83.86 (8.91)	72.64 (9.96)	78.25 (10.89)	
HbA1c (mmol/mol)	Mean (SD)	72.29 (19.43)	66.00 (14.91)	69.14 (17.29)	
High density lipoprotein (mmol/l)	Mean (SD)	1.24 (0.31)	1.19 (0.27)	1.21 (0.29)	
Cholesterol (mmol/l)	Mean (SD)	4.36 (1.13)	3.95 (0.75)	4.15 (0.97)	
Triglycerides (mmol/l)	Mean (SD)	1.68 (0.74)	2.02 (1.02)	1.85 (0.89)	
Haemoglobin (g/l)	Mean (SD)	139.21 (14.12)	139.43 (11.35)	139.32 (12.57)	
White cells (x109/l)	Mean (SD)	6.46 (2.55)	7.34 (2.04)	6.90 (2.31)	
Platelets (x109/l)	Mean (SD)	218.71 (61.85)	273.14 (81.37)	245.93 (76.15)	
Red cells (x1012/l)	Mean (SD)	4.84 (0.49)	4.71 (0.48)	4.78 (0.48)	

Variable	Summary	РСВ	AZD	Total N=28	
		N=14	N=14		
Mean corpuscular volume (fl)	Mean (SD)	88.43 (4.64)	91.21 (6.96)	89.82 (5.98)	
Haematocrit (packed cell volume)	Mean (SD)	0.43 (0.04)	0.43 (0.03)	0.43 (0.03)	
Mean corpuscular haemoglobin (pg)	Mean (SD)	28.82 (2.09)	29.74 (2.47)	29.28 (2.29)	
Corpuscular hemoglobin concentration (g/l)	Mean (SD)	325.57 (10.43)	326.64 (8.29)	326.11 (9.26)	
Red blood cell distribution width (%)	Mean (SD)	13.88 (0.98)	14.12 (1.10)	14.00 (1.03)	
Albumin (g/l)	Mean (SD)	39.43 (2.56)	39.50 (2.44)	39.46 (2.46)	
Blirubin (umol/l)	Mean (SD)	8.93 (2.97)	8.14 (2.82)	8.54 (2.87)	
Alkaline phosphatase (U/I)	Mean (SD)	80.43 (23.76)	85.07 (26.08)	82.75 (24.59)	
Alanine aminotransferase (iu/l)	Mean (SD)	24.64 (7.10)	27.43 (10.91)	26.04 (9.14)	
Aspartate aminotransferase (iu/l)	Mean (SD)	21.00 (4.95)	22.64 (5.50)	21.82 (5.20)	
Gamma-glutamyl transpeptidase (iu/l)	Mean (SD)	41.86 (33.87)	39.29 (29.87)	40.57 (31.37)	
eGFR (ml/min/1.73m2)	Mean (SD)	81.86 (9.69)	79.21 (13.59)	80.54 (11.66)	
Sodium (mmol/l)	Mean (SD)	138.93 (2.06)	140.71 (5.47)	139.82 (4.15)	
Potassium (mmol/l)	Mean (SD)	4.46 (0.33)	4.63 (0.41)	4.55 (0.37)	
Urea (mmol/l)	Mean (SD)	6.96 (2.81)	7.25 (2.17)	7.10 (2.47)	
Creatinine (umol/l)	Mean (SD)	76.64 (15.36)	76.21 (20.04)	76.43 (17.52)	
Testosterone (nmol/l)	Mean (SD)	11.10 (6.25)	6.97 (5.48)	9.04 (6.14)	
Dehydroepiandrosterone sulphate (umol/l)	Mean (SD)	3.53 (2.19)	2.91 (1.69)	3.22 (1.95)	
Free thyroxine (pmol/l)	Mean (SD)	14.86 (2.20)	15.73 (1.58)	15.30 (1.93)	
Thyroid stimulating hormone (mIU/I)	Mean (SD)	1.74 (0.66)	1.72 (0.63)	1.73 (0.64)	

Nn=Number non-missing; Q1=1st quartile; Q3=3rd quartile

# Table 2: Primary and secondary efficacy outcomes; adjusted differences between treatment groups

Population: Full analysis set. Multiple imputation was used to address missing data. Due to issues with the data distributions, for all variables except TEWL, integrity, wound diameter & depth, median regression was used to estimate confidence intervals around differences between the groups. For TEWL, integrity, wound depth and diameter, linear regression was used. TEWL and integrity measurements were log-transformed prior to analysis; differences have been expressed as ratios of geometric means (AZD:PCB). For each variable, the comparison was adjusted for baseline value of the variable (not applicable to wound diameter & depth), age, sex and baseline HbA1c. All TEWL readings were adjusted using TEWL baseline at day 0. Between group differences were not calculated for biopsy and plasma AZD4017 because available PCB values did not vary, all were below the detection limit.

D:66----

Variable	Observed med	dian (Q1, Q3)	Estimated	median*	Difference*		Co	onfidence interval	*	
	PCB	AZD	PCB N=14	AZD N=14	AZD-PCB	75%	80%	85%	90%	95%
11bHSD1 activity radioassay (% conv/24hrs): Day 28	12.0 ( 8.9, 14.5), n=13	12.7 ( 8.8, 15.6), n=14	11.8	12.8	1.1	(-2.0, 4.1)	(-2.3, 4.4)	(-2.8, 4.9)	(-3.4, 5.5)	(-4.3, 6.4)
11bHSD1 activity ELISA (% conv/24hrs): Day 28	5.6 ( 1.0, 7.6), n=13	4.3 ( 3.1, 5.0), n=14	4.9	4.3	-0.5	(-2.8, 1.7)	(-3.0, 2.0)	(-3.4, 2.3)	(-3.8, 2.7)	(-4.5, 3.4)
Sudomotor function Left Hand (micro S): Day 35	58.0 (48.0, 63.0), n=13	64.0 (59.0, 72.0), n=13	55.3	65.7	10.4	(2.0, 18.7)	(1.0, 19.7)	(-0.2, 21.0)	(-1.8, 22.6)	(-4.4, 25.1)
Sudomotor function Right Hand (micro S): Day 35	55.0 (51.0, 60.0), n=13	63.0 (57.0, 69.0), n=13	55.6	60.6	5.0	(-3.1, 13.1)	(-4.0, 14.0)	(-5.2, 15.2)	(-6.7, 16.8)	(-9.2, 19.2)
Sudomotor function Hands (micro S): Day 35	57.5 (49.5, 61.0), n=13	63.5 (59.0, 70.5), n=13	55.8	63.0	7.3	(-1.0, 15.6)	(-2.0, 16.5)	(-3.2, 17.7)	(-4.8, 19.3)	(-7.4, 21.9)
Sudomotor function Left Foot (micro S): Day 35	70.0 (61.0, 76.0), n=13	80.0 (64.0, 82.0), n=13	75.5	68.5	-7.0	(-14.8, 0.8)	(-15.7, 1.7)	(-16.9, 2.8)	(-18.4, 4.3)	(-20.7, 6.7)
Sudomotor function Right Foot (micro S): Day 35	65.0 (63.0, 75.0), n=13	80.0 (68.0, 82.0), n=13	73.0	68.9	-4.1	(-10.3, 2.2)	(-11.1, 3.0)	(-12.0, 3.9)	(-13.2, 5.1)	(-15.1, 7.0)
Sudomotor function Feet (micro S): Day 35	68.5 (62.0, 75.0), n=13	80.0 (66.0, 82.5), n=13	73.8	69.3	-4.5	(-11.4, 2.3)	(-12.2, 3.1)	(-13.2, 4.1)	(-14.5, 5.4)	(-16.6, 7.5)
Sudomotor function Overall (micro S): Day 35	59.8 (53.8, 68.0), n=13	70.8 (64.5, 73.0), n=13	65.0	63.7	-1.3	(-6.8, 4.1)	(-7.4, 4.7)	(-8.2, 5.5)	(-9.2, 6.6)	(-10.9, 8.3)
Skin hydration (A.U): Day 35	40.5 (29.4, 46.0), n=12	45.3 (37.0, 46.5), n=12	38.0	43.7	5.7	(-0.1, 11.4)	(-0.8, 12.1)	(-1.6, 13.0)	(-2.8, 14.1)	(-4.6, 15.9)
Epidermal thickness (micro m): Day 35	57.5 (55.7, 67.3), n=13	66.3 (60.6, 74.4), n=12	61.2	66.8	5.6	(-1.5, 12.7)	(-2.4, 13.5)	(-3.4, 14.6)	(-4.9, 16.0)	(-7.1, 18.3)
Cortisol (mcg/24h): Day 35	55.0 (47.0, 120.0), n=13	62.0 (52.0, 73.0), n=13	61.6	66.9	5.3	(-19.1, 29.6)	(-21.9, 32.5)	(-25.5, 36.1)	(-30.2, 40.7)	(-37.6, 48.2)
Urinary [THF+alloTHF]/THE ratio: Day 35	0.89 (0.88, 1.24), n=13	0.10 (0.08, 0.12), n=13	1.00	0.13	-0.87	(-0.98, -0.75)	(-1.00, -0.73)	(-1.01, -0.72)	(-1.04, -0.69)	(-1.07, -0.66)
Biopsy AZD4017: Day 28	<5 (<5, <5), n=13	1570 ( 876, 2440), n=14								
Plasma AZD4017: Day 35	<5 (<5, <5), n=7	6490 (2960, 9040), n=12								
Variable	Observed mean (SD)		Estimated mean* Difference*		Confidence interval*					
	PCB	AZD	PCB N=14	AZD N=14	AZD-PCB	75%	80%	85%	90%	95%
Wound gap diameter (mm): Day 2	1.49 (0.72), n=14	0.98 (0.70), n=14	1.51	0.98	-0.52	(-0.82, -0.23)	(-0.85, -0.20)	(-0.89, -0.15)	(-0.95, -0.10)	(-1.04, -0.01)
Wound depth (mm): Day 7	0.60 (0.23), n=14	0.59 (0.16), n=14	0.60	0.59	-0.01	(-0.10, 0.09)	(-0.11, 0.10)	(-0.13, 0.11)	(-0.15, 0.13)	(-0.17, 0.16)
Wound gap diameter (mm): Day 30	1.44 (0.70), n=11	0.65 (0.49), n=12	1.35	0.70	-0.65	(-0.99, -0.32)	(-1.03, -0.28)	(-1.08, -0.23)	(-1.15, -0.16)	(-1.25, -0.05)
Wound depth (mm): Day 35	0.60 (0.17), n=13	0.54 (0.21), n=12	0.59	0.56	-0.03	(-0.12, 0.05)	(-0.13, 0.06)	(-0.14, 0.07)	(-0.16, 0.09)	(-0.18, 0.12)
Variable	Observed log scale mea	Observed log scale mean (SD); geometric mean		Estimated geometric mean* Ratio*		Confidence interval*				
	PCB N=14	AZD N=14	PCB N=14	AZD N=14	AZD:PCB	75%	80%	85%	90%	95%
Hour 3 TEWL (Set 1; Day 0)	3.6 ( 0.3); 34.9, n=14	3.4 ( 0.2); 30.8, n=12	35.1	32.0	0.91	(0.81, 1.03)	(0.79, 1.05)	(0.78, 1.07)	(0.76, 1.09)	(0.73, 1.13)
Hour 48 TEWL (Set 1; Day 2)	3.0 ( 0.3); 19.8, n=14	3.1 (0.4); 21.3, n=11	20.4	20.6	1.01	(0.86, 1.19)	(0.84, 1.21)	(0.82, 1.24)	(0.79, 1.28)	(0.76, 1.34)
Hour 168 TEWL (Set 1; Day 7)	2.6 ( 0.3); 13.5, n=13	2.8 (0.7); 16.1, n=13	14.1	15.6	1.11	(0.86, 1.44)	(0.83, 1.49)	(0.80, 1.54)	(0.76, 1.62)	(0.70, 1.76)
Hour 3 TEWL (Set 2; Day 28)	3.2 ( 0.5); 23.8, n=13	3.4 ( 0.3); 29.8, n=14	23.0	30.7	1.33	(1.09, 1.63)	(1.06, 1.67)	(1.03, 1.72)	(0.99, 1.79)	(0.93, 1.90)
Hour 48 TEWL (Set 2; Day 30)	2.7 ( 0.4); 14.4, n=13	2.9 ( 0.4); 18.2, n=14	14.6	18.4	1.26	(1.03, 1.53)	(1.01, 1.56)	(0.98, 1.61)	(0.94, 1.67)	(0.89, 1.77)
Hour 168 TEWL (Set 2; Day 35)	2.3 ( 0.4); 10.0, n=13	2.4 ( 0.4); 10.8, n=12	10.1	10.8	1.07	(0.87, 1.31)	(0.85, 1.34)	(0.82, 1.38)	(0.79, 1.44)	(0.74, 1.53)
Hour 0 TEWL (Set 3; Day 35)	1.9 ( 0.4); 7.0, n=13	2.2 ( 0.5); 8.9, n=12	6.9	9.2	1.33	(1.07, 1.65)	(1.04, 1.69)	(1.01, 1.75)	(0.97, 1.82)	(0.91, 1.95)
N tapes required for barrier disruption: Day 28										

<sup>\*</sup>Estimated via multiple imputation, adjusted for baseline value (if applicable), age, sex and baseline HbA1c.

Mandali I

Table 3: Longitudinal laboratory safety variables; adjusted differences between treatment groups

Population: Safety set. All point estimates and confidence intervals estimated via linear regression.

Variable	Mean* PCB (N=14), AZD (N=14); Difference* AZD-PCB (90% CI)						
	Day 7	Day 28	Day 35	Day 42			
Body Mass Index (kg / m2)	N/A	N/A	34.53, 34.94; 0.41 (-0.51, 1.34)	N/A			
Waist-hip ratio	N/A	N/A	0.99, 1.01; 0.02 (-0.01, 0.05)	N/A			
Systolic blood pressure (mm Hg)	N/A	N/A	143.68, 128.94; -14.74 (-23.00, -6.47)	138.44, 139.20; 0.77 (-6.58, 8.11)			
Diast olic blood pressure (mm Hg)	N/A	N/A	78.00, 75.56; -2.43 (-7.67, 2.80)	78.56, 80.65; 2.09 (-6.77, 10.95)			
HbA1c (mmol/mol)	68.77, 68.95; 0.18 (-1.51, 1.88)	67.05, 69.22; 2.17 (-0.64, 4.99)	67.43, 68.16; 0.72 (-3.64, 5.09)	66.28, 68.69; 2.42 (-2.38, 7.22)			
High density lipoprotein (mmol/l)	1.13, 1.07; -0.06 (-0.14, 0.02)	1.13, 1.06; -0.08 (-0.16, 0.00)	1.09, 0.96; -0.13 (-0.21, -0.05)	1.06, 1.11; 0.05 (-0.07, 0.16)			
Cholesterol (mmol/l)	4.15, 3.74; -0.42 (-0.60, -0.23)	4.10, 3.64; -0.46 (-0.79, -0.12)	4.00, 3.49; -0.51 (-0.87, -0.15)	3.91, 3.81; -0.10 (-0.54, 0.34)			
Triglycerides (mmol/l)	2.32, 2.18; -0.14 (-0.67, 0.40)	2.12, 1.93; -0.19 (-0.56, 0.18)	2.96, 2.48; -0.48 (-1.21, 0.24)	2.79, 2.81; 0.02 (-0.51, 0.55)			
Haemoglobin (g/l)	136.42, 137.08; 0.67 (-2.12, 3.45)	136.91, 135.94; -0.98 (-4.13, 2.17)	133.37, 134.00; 0.64 (-3.96, 5.24)	131.15, 133.22; 2.07 (-1.62, 5.76)			
White cells (x109/I)	7.06, 7.60; 0.54 (-0.14, 1.22)	6.93, 6.54; -0.40 (-0.87, 0.08)	6.97, 6.67; -0.31 (-0.96, 0.34)	6.98, 7.31; 0.33 (-0.41, 1.07)			
Platelets (x109/l)	246.02, 248.45; 2.42 (-13.65, 18.50)	247.32, 260.65; 13.32 (-9.56, 36.20)	241.23, 240.32; -0.91 (-25.20, 23.37)	245.18, 246.65; 1.47 (-16.74, 19.68)			
Red cells (x1012/l)	4.69, 4.64; -0.05 (-0.17, 0.06)	4.70, 4.65; -0.05 (-0.15, 0.04)	4.56, 4.55; -0.02 (-0.15, 0.12)	4.45, 4.60; 0.15 (0.03, 0.26)			
Mean corpuscular volume (fl)	90.88, 90.99; 0.11 (-1.83, 2.05)	90.48, 91.00; 0.52 (-1.49, 2.53)	91.91, 91.74; -0.17 (-2.53, 2.19)	91.01, 91.17; 0.16 (-1.42, 1.73)			
Haematocrit (packed cell volume)	0.43, 0.42; -0.01 (-0.02, 0.01)	0.42, 0.43; 0.00 (-0.01, 0.02)	0.41, 0.41; 0.00 (-0.02, 0.02)	0.40, 0.41; 0.02 (0.00, 0.03)			
Mean corpuscular haemoglobin (pg)	29.26, 29.67; 0.41 (0.08, 0.75)	29.34, 29.27; -0.07 (-0.44, 0.31)	29.46, 29.63; 0.17 (-0.28, 0.62)	29.60, 29.17; -0.42 (-0.95, 0.10)			
Corpuscular hemoglobin concentration (g/l)	321.59, 326.49; 4.91 (-1.41, 11.22)	326.54, 322.74; -3.80 (-10.80, 3.21)	322.83, 324.58; 1.75 (-4.85, 8.35)	327.15, 321.93; -5.22 (-12.18, 1.74)			
Red blood cell distribution width (%)	14.52, 14.17; -0.36 (-0.89, 0.18)	14.36, 14.27; -0.09 (-0.49, 0.31)	14.52, 14.63; 0.11 (-0.28, 0.51)	14.23, 14.03; -0.21 (-0.68, 0.26)			
Albumin (g/l)	39.64, 40.01; 0.37 (-0.82, 1.55)	39.14, 38.77; -0.37 (-1.82, 1.09)	39.73, 39.73; -0.01 (-1.60, 1.59)	38.52, 38.91; 0.40 (-0.59, 1.38)			
Blirubin (umol/l)	8.03, 8.96; 0.93 (-1.14, 3.00)	9.06, 9.67; 0.60 (-0.89, 2.09)	9.14, 8.50; -0.64 (-3.01, 1.73)	8.44, 8.79; 0.35 (-1.17, 1.87)			
Alkaline phosphatase (U/I)	83.41, 77.41; -6.00 (-12.44, 0.44)	80.09, 67.71; -12.39 (-20.21, -4.56)	77.45, 64.36; -13.09 (-20.43, -5.75)	75.90, 70.24; -5.65 (-15.25, 3.95)			
Alanine aminotransferase (iu/l)	23.94, 25.10; 1.16 (-1.84, 4.15)	22.46, 20.50; -1.96 (-4.94, 1.03)	21.13, 19.49; -1.64 (-5.88, 2.61)	18.78, 19.56; 0.78 (-3.00, 4.56)			
Aspartate aminotransferase (iu/l)	21.49, 21.95; 0.46 (-2.29, 3.21)	20.81, 20.93; 0.12 (-1.81, 2.05)	20.63, 20.59; -0.04 (-2.52, 2.45)	18.88, 21.09; 2.21 (-1.02, 5.44)			
Gamma-glutamyl transpeptidase (iu/l)	38.34, 39.10; 0.76 (-2.83, 4.35)	39.34, 29.06; -10.28 (-14.96, -5.60)	40.60, 28.62; -11.97 (-22.80, -1.15)	39.57, 30.03; -9.55 (-14.88, -4.22)			
eGFR (ml/min/1.73m2)	76.12, 72.94; -3.18 (-8.30, 1.94)	74.78, 72.59; -2.19 (-5.38, 1.01)	68.65, 68.92; 0.27 (-4.57, 5.10)	65.69, 67.31; 1.62 (-2.77, 6.01)			
Sodium (mmol/l)	139.60, 139.70; 0.10 (-1.23, 1.44)	138.37, 138.52; 0.16 (-0.98, 1.29)	140.03, 138.84; -1.19 (-3.21, 0.82)	139.07, 137.82; -1.25 (-2.42, -0.07)			
Potassium (mmol/l)	4.85, 4.54; -0.31 (-0.58, -0.03)	4.68, 4.86; 0.18 (-0.06, 0.43)	4.53, 4.54; 0.01 (-0.22, 0.25)	4.65, 4.61; -0.04 (-0.31, 0.22)			
Urea (mmol/l)	7.02, 7.15; 0.13 (-0.79, 1.05)	6.72, 6.37; -0.35 (-1.31, 0.61)	7.34, 6.82; -0.52 (-1.88, 0.83)	7.51, 7.53; 0.02 (-1.04, 1.08)			
Creatinine (umol/l)	81.73, 89.16; 7.43 (0.79, 14.08)	83.09, 86.52; 3.43 (-0.98, 7.85)	91.89, 93.67; 1.78 (-5.65, 9.22)	95.86, 94.28; -1.58 (-8.24, 5.07)			
Testosterone (nmol/l)	8.70, 8.06; -0.63 (-2.52, 1.25)	8.98, 7.92; -1.06 (-2.58, 0.45)	8.51, 8.10; -0.40 (-2.66, 1.85)	7.96, 9.08; 1.12 (-1.20, 3.45)			
Dehydroepiandrosterone sulphate (umol/l)	3.09, 5.39; 2.30 (1.52, 3.08)	2.74, 5.60; 2.86 (2.09, 3.64)	2.65, 4.82; 2.16 (1.29, 3.04)	2.30, 3.39; 1.09 (0.43, 1.75)			
Free thyroxine (pmol/l)	14.94, 15.44; 0.50 (-0.63, 1.64)	14.71, 15.21; 0.51 (-0.43, 1.44)	14.32, 14.97; 0.65 (-0.45, 1.76)	13.61, 14.41; 0.79 (0.07, 1.52)			
Thyroid stimulating hormone (mIU/I)	1.71, 1.81; 0.10 (-0.22, 0.42)	1.87, 1.68; -0.20 (-0.58, 0.19)	1.89, 1.74; -0.15 (-0.54, 0.23)	1.95, 1.91; -0.04 (-0.46, 0.38)			

<sup>\*</sup>Estimated in imputed data, adjusted for baseline value, age, sex and baseline HbA1c.

**Table 4: Adverse event summary** 

Population: Safety set

Adverse events (AE)	PCB (n=14)	AZD (n=14)	All patients (n=28)
Total AE: n (n per PY)	13 (8.3)	24 (13.8)	37 (11.1)
Unique AE: n (n per PY)	13 (8.3)	16 (9.2)	29 (8.7)
Patients with >=1 AE: n (%)	8 (57)	10 (71)	18 (64)
Discontinuation due to AE: n (%)	0 (-)	0 (-)	0 (-)
AE by SOC: n total (n unique*), n patients (%)			
Blood	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Cardiac	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Congenital	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Ear	0 (0), 0 (-)	0 (0), 0 (-)	0(0),0(-)
Endocrine	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Eye	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Gastrointestinal	9 (9), 6 (43)	14 (8), 7 (50)	23 (17), 13 (46)
General	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Hepatobiliary	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Immune	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Infections	0 (0), 0 (-)	1(1), 1(7)	1(1), 1(4)
Injury	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Investigations	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Metabolism	0 (0), 0 (-)	0 (0), 0 (-)	0(0),0(-)
Musculoskeletal	0 (0), 0 (-)	1(1), 1(7)	1(1), 1(4)
Neoplasms	0 (0), 0 (-)	0 (0), 0 (-)	0(0),0(-)
Nervous system	1(1), 1(7)	6 (4), 4 (29)	7 (5), 5 (18)
Pregnancy	0 (0), 0 (-)	0 (0), 0 (-)	0(0),0(-)
Psychiatric	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Renal	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Reproductive system	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Respiratory	2 (2), 1 (7)	2 (2), 1 (7)	4 (4), 2 (7)
Skin	1(1), 1(7)	0 (0), 0 (-)	1(1), 1(4)
Social	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Surgical	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Vascular	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
AE severity: n*			
Mild	13	13	26
Moderate	0	3	3
Severe	0	0	0
Life-threatening	0	0	0
Death	0	0	0
AE by relation to study drug: n*			
Not related	0	1	1
Unlikely	4	4	8
Possi ble	9	11	20
Probable	0	0	0
Definite	0	0	0
SAE			
Total SAE: n	0	1	1
Patients with >=1 SAE: n (%)	O (-)	1 (7)	1(4)

<sup>\*</sup>Recurrent AEs counted once at maximum severity/relatedness reported. SOC=CTCAE system order class; PY=patient year